We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Uptake of Next-Generation Sequencing in Europe Driven Largely by Personalized Medicine Developments

By LabMedica International staff writers
Posted on 02 Jun 2014
Print article
A new Frost & Sullivan (San Antonio, TX, USA) analysis has found the Western European next-generation sequencing (NGS) market poised for steady growth, owing to the emergence of many new applications.

The new report, "Western European Next-Generation Sequencing Markets," indicates that growth will continue with the emergence of applications such as noninvasive prenatal testing and comprehensive oncology panels. NGS companies are further tapping into this space by forming partnerships with molecular diagnostic companies to quicken NGS adoption in clinics, particularly for oncology-based testing. Also, the future of DNA sequencing is predicted to shift from a laboratory-based setup to point-of-care testing in the next 5 years.

The report found that the market earned revenues of USD 381.9 million in 2013 and estimates this to reach USD 697.3 million in 2018. The total market, as defined by this study, includes next-generation sequencers and reagents for both research and diagnostic use. Major medical growth areas will include preimplantation genetic diagnosis, oncology testing, infectious disease, human leukocyte antigen typing, and companion diagnostics. Also, as applications expand to include food and safety testing (as well as crop improvement), ready-to-use sequencing-based tests that generate data from raw samples will emerge as important tools.

A key restraint curbing market potential is the lack of reimbursement norms, which leads to geographical disparity in terms of NGS test availability. The consequent need for the cross-border shipping of samples, prominent in Belgium, France, Italy, Spain, the UK, and Germany, makes gauging the reimbursement scenario extremely tough for market participants. Hence, NGS vendors must establish early, robust partnerships with regulatory bodies and devise effective business models to gain rapid regulatory clearance. Manufacturers must also look to adhere to the CE marking rather than laboratory developed test (LDT) policies to enable the easy generation of reimbursement codes.

"Companies within the space of personalized healthcare are designing instruments to target specific needs across the clinical diagnostic spectrum, therefore adding NGS capabilities to their portfolio," said Divyaa Ravishankar, Healthcare Senior Industry Analyst at Frost & Sullivan. "As long as the genomic era interfaces with personalized medicine, NGS uptake will continue."

"Given the recent technology advancements in Europe, the future of DNA sequencing will move away from a laboratory-based setup to point-of-care testing," predicted Ms. Ravishankar. "Frost & Sullivan expects NGS to become an area of interest to all market leaders within the point-of-care testing domain, as they strive to bring sequencing from 'bench to bedside'."

Related Links:

Frost & Sullivan
Life Sciences Growth Partnership Service program


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.